HTBX - Heat Biologics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6099
+0.0199 (+3.37%)
As of 3:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.5900
Open0.6047
Bid0.6052 x 3100
Ask0.6200 x 900
Day's Range0.6031 - 0.6200
52 Week Range0.4600 - 2.2400
Volume31,678
Avg. Volume197,446
Market Cap20.777M
Beta (3Y Monthly)2.96
PE Ratio (TTM)N/A
EPS (TTM)-0.6540
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.88
Trade prices are not sourced from all markets
  • Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Collapsed 99%
    Simply Wall St.

    Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Collapsed 99%

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...

  • Zacks Small Cap Research

    HTBX: HS-130 Ready To Go

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Second Quarter 2019 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported second quarter 2019 results in an August 14 release and ...

  • Benzinga

    10 Biopharmaceutical Companies Trying To Cure Cancer

    Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated ...

  • ACCESSWIRE

    Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update

    Completed enrollment of Phase 2 non-small cell lung cancer trial; on track to report top line data later this year Received FDA clearance of IND application for Phase 1 trial of HS-130 in combination with ...

  • ACCESSWIRE

    Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110

    DURHAM, NC / ACCESSWIRE / August 12, 2019 / Heat Biologics, Inc. (HTBX), a clinical-stage biopharmaceutical company specialized in the development of therapeutics designed to activate a patient’s immune system against cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of HS-130, in combination with HS-110, for patients with advanced solid tumors refractory to standard of care. HS-130 is Heat’s allogeneic (“off-the-shelf”) cell line engineered to express the extracellular domain of OX40 ligand fusion protein (OX40L-Fc), a key costimulator of T cells, with the potential to augment antigen-specific CD8+ T cell response. HS-130 was manufactured by utilizing the Company’s proprietary process of reprogramming a live, genetically modified cell line.

  • ACCESSWIRE

    Heat Biologics CEO and Lead Director to Participate in German Investor Forums

    DURHAM, NC / ACCESSWIRE / August 7, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing therapies designed to activate a patient’s immune system against cancer, today announced ...

  • What You Must Know About Heat Biologics, Inc.'s (NASDAQ:HTBX) Beta Value
    Simply Wall St.

    What You Must Know About Heat Biologics, Inc.'s (NASDAQ:HTBX) Beta Value

    If you own shares in Heat Biologics, Inc. (NASDAQ:HTBX) then it's worth thinking about how it contributes to the...

  • ACCESSWIRE

    Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial

    DURHAM, NC / ACCESSWIRE / July 9, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient’s immune system against cancer, today announced it has completed recruitment for enrollment in its Phase 2 study investigating HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) or Merck's pembrolizumab (Keytruda®). Lori McDermott, Heat’s VP of Clinical Development, said, “We are pleased to report that our Phase 2 enrollment targets were achieved on schedule. Last month, we reported promising interim results from the study showing that the addition of HS-110 to nivolumab may restore anti-tumor activity in patients whose disease has progressed after checkpoint inhibitor therapy.

  • Zacks Small Cap Research

    HTBX: INDs To Be Filed Soon

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT First Quarter 2019 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported first quarter 2019 results in a May 15 release and concurrently ...

  • ACCESSWIRE

    Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

    Clinicalbenefit observed in 55% of patients receiving HS-110 plus nivolumab aftercheckpoint inhibitor treatment failure HS-110 incombination with nivolumab demonstrates clinical activity in low CD8+ TIL ...

  • Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?
    Simply Wall St.

    Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?

    Jeff Wolf has been the CEO of Heat Biologics, Inc. (NASDAQ:HTBX) since 2008. This analysis aims first to contrast CEO...

  • ACCESSWIRE

    Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

    DURHAM, NC / ACCESSWIRE / May 20, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23rd, at 3:00 PM, PST at The Beverly Hilton in Beverly Hills, California. Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting a company overview. Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using CD8+ "Killer" T-cells.

  • ACCESSWIRE

    Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

    On track to complete enrollment of Phase 2 lung cancer trial in Q2 2019 and report additional interim data in Q4 2019 Anticipates receiving additional $6.9 million in grant funds after filing PTX-35 IND ...

  • ACCESSWIRE

    Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

    DURHAM, NC / ACCESSWIRE / May 6, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today ...

  • ACCESSWIRE

    Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

    DURHAM, NC / ACCESSWIRE / April 18, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces ...

  • Zacks Small Cap Research

    HTBX: 2018 Financial & Operational Results

    By John Vandermosten, CFA NASDAQ:HTBX READ THE LATEST HTBX RESEARCH REPORT Full Year 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported full year 2018 results in a March 28 release and concurrently ...

  • ACCESSWIRE

    Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019

    DURHAM, NC / ACCESSWIRE / April 2, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces that it delivered a poster presentation yesterday, April 1, 2019, at the American Association for Cancer Research (AACR) Annual Meeting. The Company's presentation, entitled, ''Generation of a novel, allogeneic cell-based, Gp96-Ig/OX40L cancer vaccine, improves anti-tumor immunity and long-term memory T-cell generation,'' is available online here. The poster presentation featured the Company's next generation cellular vaccine platform, ComPACT (COMbination Pan-Antigen Cytotoxic Therapy), which incorporates a tumor antigen chaperone (gp96-Ig) with T-cell costimulation (OX40L-Ig), simulating a single tumor cell line source that secretes both products.

  • ACCESSWIRE

    Heat Biologics Reports 2018 Results and Provides Corporate Update

    Recently announced interim HS-110 Phase 2 data demonstrating survival benefit in patients with ‘cold' tumors (CD8+ TILs

  • ACCESSWIRE

    Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy

    DURHAM, NC / ACCESSWIRE / March 21, 2019 / Heat Biologics,Inc. (HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced an oral presentation to be held at the Chinese Society for Clinical Oncology (CSCO) Conference on Immunotherapy, endorsed by the American Association for Cancer Research (AACR), taking place in Shanghai, China. The oral session will be held on March 22, 2019 from 17:00 China Standard Time.

  • Zacks Small Cap Research

    HTBX: HS-110 Interim Update

    By John Vandermosten, CFA NASDAQ:HTBX Heat Biologics, Inc. (NASDAQ:HTBX) has continued to progress in their HS-110 Durga trial, recently providing interim results at the ASCO-SITC Clinical Immuno-Oncology ...

  • ACCESSWIRE

    Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai

    DURHAM, NC / ACCESSWIRE / March 5, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing "off-the-shelf" T-cell therapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, will chair a roundtable discussion at 4:00-5:00 pm China Standard Time (CST), on Wednesday, March 6, 2019 at the WuXi Healthcare Forum at the St. Regis Shanghai Jingan Hotel. Dr. Prendergast will chair a panel on oncology, which will focus on promising new developments in the space.

  • ACCESSWIRE

    Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium

    - Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy - Median overall survival not yet reached ...

  • ACCESSWIRE

    These Four Healthcare Stocks Are Heating Up On Tuesday

    Premier Health Group (PHGRF) (PHGI), Heat Biologics Inc (HTBX), Zynerba Pharmaceuticals Inc (ZYNE), and Aurora Cannabis Inc (ACB) represent 4 healthcare stocks to keep on your radar this week. Premier Health Group (PHGRF) (PHGI) today announced plans to expand its development team at Cloud Practice Inc. to support the Company's focus on digitizing health care. The Company recently hired four new full-time employees, three Web Software Developers and one User Interface/User Experience (UI/UX) Designer, to support the build-out of its patient-centric platform and mobile app - a beta version of which will be available by end of Q2.

  • What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?
    Simply Wall St.

    What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Heat Biologics, Inc. (NASDAQ:HTBX)Read More...

  • ACCESSWIRE

    UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

    DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).